USD 200m Series A funds of Windward Bio: the advisors
BGPartner has advised OrbiMed and Novo Holdings on Swiss legal matters related to the USD 200 million Series A financing of Windward Bio Group, a Swiss-based clinical-stage drug development company, advised by Homburger.
The financing round was led by OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities, with additional investment from SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners.
The proceeds will fund the development of Windward Bio’s phase 2-ready, long-acting anti-TSLP antibody, which is under investigation for potential applications in asthma and chronic obstructive pulmonary disease (COPD).
The Team
The BGPartner team included Oliver Gnehm (Partner), Victoria Marty (Senior Associate), and Tessa Douma (Associate).
The Homburger team comprises Andreas Müller, Margrit Marti, Oliver Kneubühl, Kaiyan Yeo, Eric Hubber, Jonas Stähli, Rebecca Sigrist and Carolina Rodriguez (all Corporate / M&A), Stefan Oesterhelt and Juliette Buob (both Tax) and Luca Dal Molin (IP / IT).
